Up-regulation of hTERT expression by low-dose cisplatin contributes to chemotherapy resistance in human hepatocellular cancer cells

Oncology Reports

Volumn 22, Issue 3, 2009, Pages 549-556

  Guo, Xian Ling ^a,b   Ma, Nan Nan ^a   Zhou, Fei Guo ^a   Zhang, Li ^a   Bu, Xin Xin ^a   Sun, Kai ^a   Song, Jian Rui ^a   Li, Rong ^a   Zhang, Bai He ^a   Wu, Meng Chao ^a   Wei, Li Xin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Hang Zhou Sanitarium of PLA   (China)

Author keywords

Cisplatin; Hepatocellular carcinoma; Human telomerase reverse transcriptase; NF B; Telomerase

Indexed keywords

CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR RELA; ANTINEOPLASTIC AGENT; TERT PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LOW DRUG DOSE; PRIORITY JOURNAL; UPREGULATION; DNA DAMAGE; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CISPLATIN; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIVER NEOPLASMS; NF-KAPPA B; TELOMERASE; UP-REGULATION;

EID: 70349305615     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000470     Document Type: Article

References (42)

1. Greider CW and Blackburn EH: Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43: 405-413, 1985.
2. Greider CW and Blackburn EH: A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 337: 331-337, 1989.
3. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
4. Shay JW and Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 33: 787-791, 1997.
5. Takakura M, Kyo S, Kanaya T, Tanaka M and Inoue M: Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res 58: 1558-1561, 1998.
6. Kyo S, Kanaya T, Takakura M, Tanaka M and Inoue M: Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues. Int J Cancer 80: 60-63, 1999.
7. Kyo S, Kanaya T, Takakura M, Tanaka M, Yamashita A, Inoue H and Inoue M: Expression of human telomerase subunits in ovarian malignant, borderline and benign tumors. Int J Cancer 80: 804-809, 1999.
8. Cong YS, Wen J and Bacchetti S: The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 8: 137-142, 1999.
9. Horikawa I, Cable PL, Afshari C and Barrett JC: Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 59: 826-830, 1999.
10. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA and Weinberg RA: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795, 1997.
11. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M and Inoue M: Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59: 551-557, 1999.
12. Lu C, Fu W and Mattson MP: Telomerase protects developing neurons against DNA damage-induced cell death. Brain Res Dev Brain Res 131: 167-171, 2001.
13. Holt SE, Glinsky VV, Ivanova AB and Glinsky GV: Resistance to apoptosis in human cells conferred by telomerase function and telomere stability. Mol Carcinog 25: 241-248, 1999.
14. Faraoni I, Turriziani M, Masci G, De Vecchis L, Shay JW, Bonmassar E and Graziani G: Decline in telomerase activity as a measure of tumor cell killing by antineoplastic agents in vitro. Clin Cancer Res 3: 579-585, 1997.
15. Asai A, Kiyozuka Y, Yoshida R, Fujii T, Hioki K and Tsubura A: Telomere length, telomerase activity and telomerase RNA expression in human esophageal cancer cells: correlation with cell proliferation, differentiation and chemosensitivity to anticancer drugs. Anticancer Res 18: 1465-1472, 1998.
16. Lin Z, Lim S, Viani MA, Sapp M and Lim MS: Down-regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agents. Am J Pathol 159: 711-719, 2001.
17. Sato N, Mizumoto K, Kusumoto M, Nishio S, Maehara N, Urashima T, Ogawa T and Tanaka M: Up-regulation of telomerase activity in human pancreatic cancer cells after exposure to etoposide. Br J Cancer 82: 1819-1826, 2000.
18. Kuranaga N, Shinomiya N and Mochizuki H: Long-term cultivation of colorectal carcinoma cells with anti-cancer drugs induces drug resistance and telomere elongation: an in vitro study. BMC Cancer 1: 10, 2001.
19. Moriarty TJ, Dupuis S and Autexier C: Rapid upregulation of telomerase activity in human leukemia HL-60 cells treated with clinical doses of the DNA-damaging drug etoposide. Leukemia 16: 1112-1120, 2002.
20. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
21. Roberts LR and Gores GJ: Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 25: 212-225, 2005.
22. Burger AM, Double JA and Newell DR: Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur J Cancer 33: 638-644, 1997.
23. Akiyama M, Horiguchi-Yamada J, Saito S, Hoshi Y, Yamada O, Mizoguchi H and Yamada H: Cytostatic concentrations of anticancer agents do not affect telomerase activity of leukaemic cells in vitro. Eur J Cancer 35: 309-315, 1999.
24. Wang S and Zhu J: Evidence for a relief of repression mechanism for activation of the human telomerase reverse transcriptase promoter. J Biol Chem 278: 18842-18850, 2003.
25. Chen J, Yan Y, Li J, Ma Q, Stoner GD, Ye J and Huang C: Differential requirement of signal pathways for benzo[a]pyrene (B[a]P)-induced nitric oxide synthase (iNOS) in rat esophageal epithelial cells. Carcinogenesis 26: 1035-1043, 2005.
26. Takakura M, Kyo S, Inoue M, Wright WE and Shay JW: Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT) in human and mouse cells. Mol Cell Biol 25: 8037-8043, 2005.
27. Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M and Cheng AL: Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol 63: 1709-1716, 2002.
28. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O and Sarkar FH: Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65: 6934-6942, 2005.
29. Yeh PY, Chuang SE, Yeh KH, Song YC and Cheng AL: Involvement of nuclear transcription factor-kappa B in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells. Biochem Pharmacol 66: 25-33, 2003.
30. Sheng WY, Chen YR and Wang TC: A major role of PKC theta and NFkappaB in the regulation of hTERT in human T lymphocytes. FEBS Lett 580: 6819-6824, 2006.
31. Sinha-Datta U, Horikawa I, Michishita E, Datta A, Sigler-Nicot JC, Brown M, Kazanji M, Barrett JC and Nicot C: Transcriptional activation of hTERT through the NF-kappaB pathway in HTLV-I-transformed cells. Blood 104: 2523-2531, 2004.
32. Zunino F, Perego P, Pilotti S, Pratesi G, Supino R and Arcamone F: Role of apoptotic response in cellular resistance to cytotoxic agents. Pharmacol Ther 76: 177-185, 1997.
33. Akiyama M, Yamada O, Kanda N, Akita S, Kawano T, Ohno T, Mizoguchi H, Eto Y, Anderson KC and Yamada H: Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. Cancer Lett 178: 187-197, 2002.
34. Gorbunova V, Seluanov A and Pereira-Smith OM: Expression of human telomerase (hTERT) does not prevent stress-induced senescence in normal human fibroblasts but protects the cells from stress-induced apoptosis and necrosis. J Biol Chem 277: 38540-38549, 2002.
35. Neuhof D, Ruess A, Wenz F and Weber KJ: Induction of telomerase activity by irradiation in human lymphoblasts. Radiat Res 155: 693-697, 2001.
36. Sharma GG, Gupta A, Wang H, Scherthan H, Dhar S, Gandhi V, Iliakis G, Shay JW, Young CS and Pandita TK: hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene 22: 131-146, 2003.
37. Lee KH, Rudolph KL, Ju YJ, Greenberg RA, Cannizzaro L, Chin L, Weiler SR and DePinho RA: Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc Natl Acad Sci USA 98: 3381-3386, 2001.
38. Wong KK, Chang S, Weiler SR, Ganesan S, Chaudhuri J, Zhu C, Artandi SE, Rudolph KL, Gottlieb GJ, Chin L, Alt FW and DePinho RA: Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat Genet 26: 85-88, 2000.
39. Gately DP and Howell SB: Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67: 1171-1176, 1993.
40. Mistry P, Kelland LR, Abel G, Sidhar S and Harrap KR: The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64: 215-220, 1991.
41. Eastman A and Schulte N: Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 27: 4730-4734, 1988.
42. Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, Harley CB and von Zglinicki T: Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res 61: 3053-3061, 2001.